文献速递糖尿病

口服司美格鲁肽对2型糖尿病患者肾脏结局的影响:SOUL随机试验结果

Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.
PubMed 文献 · Diabetes Care · 2026-01-01

SOUL试验为双盲随机对照研究,纳入9,650例合并ASCVD和/或CKD的T2D患者,比较口服司美格鲁肽与安慰剂。结果显示五点和四点肾脏复合结局无显著降低,但口服司美格鲁肽使eGFR年下降更慢(-1.67 vs -2.06 mL/min/1.73 m2,估计治疗差异0.40,95%CI 0.27-0.53,P<0.0001)。

要点

  • 口服司美格鲁肽未显著降低五点或四点肾脏复合结局风险。
  • 口服司美格鲁肽使eGFR年下降更慢,估计治疗差异0.40 mL/min/1.73 m2。
  • 基线eGFR<60 mL/min/1.73 m2等多数亚组结果一致。

核心结论

  • 在eGFR总体大多保留的T2D合并ASCVD和/或CKD人群中,口服司美格鲁肽未显著减少不良肾脏结局,但减缓了eGFR下降。

研究设计与样本

  • SOUL(NCT03914326)为双盲随机对照试验,比较口服司美格鲁肽与安慰剂,共纳入9,650例T2D合并ASCVD和/或CKD患者,随访47.5个月。

主要发现

  • 五点结局在口服司美格鲁肽组403例(8.4%)、安慰剂组435例(9.0%)发生,HR 0.91(95%CI 0.80-1.05,P=0.19)。
  • 四点结局分别为112例(2.3%)与129例(2.7%),HR 0.86(95%CI 0.66-1.10,P=0.22)。
  • eGFR年下降口服司美格鲁肽组-1.67 mL/min/1.73 m2,安慰剂组-2.06 mL/min/1.73 m2,估计治疗差异0.40(95%CI 0.27-0.53,P<0.0001)。
  • 多数亚组(包括基线eGFR<60 mL/min/1.73 m2)结果相似,两组严重不良事件发生率相近。

关键数值与推荐

  • 五点复合结局包括eGFR下降≥50%、持续性eGFR<15 mL/min/1.73 m2、启动慢性肾脏替代治疗或肾脏/CV原因死亡。
  • 四点复合结局为五点复合结局排除CV死亡。
  • 基线平均eGFR为73.8 mL/min/1.73 m2。

临床怎么用

  • 对T2D合并ASCVD和/或CKD且eGFR总体保留者,口服司美格鲁肽虽未显著减少硬肾脏复合终点,但可减缓eGFR下降。
  • 临床决策仍需结合CV获益与肾脏保护的综合评估。

局限性

  • 肾脏复合结局未达统计学显著,eGFR下降减缓为主要阳性发现。
  • 人群eGFR总体大多保留,结论外推至严重肾功能不全者需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the effects of oral semaglutide on kidney outcomes in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS: SOUL (NCT03914326), a double-blind randomized controlled trial, compared oral semaglutide with placebo in people with T2D, ASCVD, and/or CKD, showing a 14% reduction in risk of major adverse cardiovascular (CV) events. Prespecified kidney outcomes included a five-point composite (≥50% decrease in estimated glomerular filtration rate [eGFR], persistent eGFR <15 mL/min/1.73 m2, initiation of chronic kidney replacement therapy, or death from kidney or CV causes); a four-point composite (excluding CV death); and eGFR decline. Prespecified subgroups were also assessed, including those with eGFR <60 mL/min/1.73 m2 at baseline. RESULTS: Among 9,650 participants, mean eGFR was 73.8 mL/min/1.73 m2, and follow-up was 47.5 months. The five-point outcome occurred in 403 (8.4%) and 435 (9.0%) participants taking oral semaglutide versus placebo, respectively (hazard ratio [HR] 0.91; 95% CI 0.80, 1.05; P = 0.19). The four-point outcome occurred in 112 (2.3%) and 129 (2.7%) participants, respectively (HR 0.86; 95% CI 0.66, 1.10; P = 0.22). Mean annual eGFR decline was less with oral semaglutide than placebo (-1.67 vs. -2.06 mL/min/1.73 m2; estimated treatment difference 0.40 [95% CI 0.27, 0.53; P < 0.0001). These effects were similar across most subgroups, including those with eGFR <60 mL/min/1.73 m2. Serious adverse events occurred at similar rates in both groups. CONCLUSIONS: In people with T2D and ASCVD and/or CKD but with overall mostly preserved eGFR, orally administered semaglutide, compared with placebo, did not significantly reduce adverse kidney outcomes but did slow the decline in eGFR.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Mann JFE, Marx N, Deanfield JE, et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care. 2026. PMID: 41380027. doi:10.2337/dc25-1080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。